Fifty 1 Labs, Inc. to Host Virtual Shareholder Teleconference Featuring World-Class Leadership Team, including Dr. James Orbinski, who received the Nobel Peace Prize on Behalf of Médecins Sans Frontières
Fifty 1 Labs (OTC: FITY), an AI-powered health and wellness solutions company, announced a virtual shareholder teleconference scheduled for July 28, 2025, at 12:00 PM EST. The event will feature Nobel Peace Prize recipient Dr. James Orbinski and showcase the company's world-class leadership team.
The company outlined its strategic roadmap, including a $1 million R&D investment in AI therapies, plans for a $5-10 million biotech acquisition by July 2027, and intentions to uplist to OTCQB by Q1 2026. Management has demonstrated commitment by investing $350,000 personally and deferring salaries until reaching a $50 million valuation.
The leadership team includes CEO Paul Arora, Dr. James Orbinski as Senior Scientist, and other notable experts in biotech, AI, and healthcare. The company focuses on AI-driven drug repurposing in the functional medicine market, projected to grow at a 10.9% CAGR through 2030.
Fifty 1 Labs (OTC: FITY), un'azienda specializzata in soluzioni per la salute e il benessere basate sull'intelligenza artificiale, ha annunciato una teleconferenza virtuale per gli azionisti programmata per il 28 luglio 2025 alle 12:00 EST. L'evento vedrà la partecipazione del premio Nobel per la Pace Dr. James Orbinski e presenterà il team di leadership di livello mondiale dell'azienda.
L'azienda ha illustrato la sua roadmap strategica, che include un investimento di 1 milione di dollari in ricerca e sviluppo dedicato alle terapie AI, piani per un'acquisizione biotech da 5-10 milioni di dollari entro luglio 2027 e l'intenzione di quotarsi sull'OTCQB entro il primo trimestre del 2026. Il management ha dimostrato impegno investendo personalmente 350.000 dollari e rinviando gli stipendi fino al raggiungimento di una valutazione di 50 milioni di dollari.
Il team di leadership comprende il CEO Paul Arora, il Dr. James Orbinski come Senior Scientist e altri esperti di rilievo nei settori biotech, AI e sanità. L'azienda si concentra sul riposizionamento di farmaci guidato dall'AI nel mercato della medicina funzionale, previsto in crescita con un CAGR del 10,9% fino al 2030.
Fifty 1 Labs (OTC: FITY), una empresa de soluciones para la salud y el bienestar impulsadas por inteligencia artificial, anunció una teleconferencia virtual para accionistas programada para el 28 de julio de 2025 a las 12:00 PM EST. El evento contará con la participación del premio Nobel de la Paz Dr. James Orbinski y presentará al equipo de liderazgo de clase mundial de la compañía.
La empresa detalló su hoja de ruta estratégica, que incluye una inversión de 1 millón de dólares en I+D para terapias basadas en IA, planes para una adquisición biotecnológica de 5 a 10 millones de dólares antes de julio de 2027 y la intención de ascender a OTCQB para el primer trimestre de 2026. La gerencia ha demostrado compromiso invirtiendo personalmente 350,000 dólares y posponiendo sus salarios hasta alcanzar una valoración de 50 millones de dólares.
El equipo de liderazgo incluye al CEO Paul Arora, al Dr. James Orbinski como Científico Senior y otros expertos destacados en biotecnología, IA y atención médica. La empresa se enfoca en la reutilización de medicamentos impulsada por IA en el mercado de medicina funcional, proyectado para crecer a una Tasa Compuesta Anual del 10.9% hasta 2030.
Fifty 1 Labs (OTC: FITY)는 AI 기반 건강 및 웰니스 솔루션 회사로, 2025년 7월 28일 오후 12시 EST에 가상 주주 전화회의를 개최할 예정이라고 발표했습니다. 이번 행사에는 노벨 평화상 수상자인 Dr. James Orbinski가 참여하며, 회사의 세계적 수준의 리더십 팀이 소개됩니다.
회사는 AI 치료제 연구개발에 100만 달러 투자, 2027년 7월까지 500만~1000만 달러 규모의 바이오테크 인수 계획, 2026년 1분기까지 OTCQB 상장 추진 계획 등 전략적 로드맵을 제시했습니다. 경영진은 35만 달러를 개인 투자하고, 회사 가치가 5000만 달러에 도달할 때까지 급여를 유예하는 등 의지를 보였습니다.
리더십 팀에는 CEO Paul Arora, 수석 과학자 Dr. James Orbinski 및 바이오테크, AI, 헬스케어 분야의 저명한 전문가들이 포함되어 있습니다. 회사는 기능성 의학 시장에서 AI 기반 약물 재활용에 집중하고 있으며, 이 시장은 2030년까지 연평균 성장률 10.9%가 예상됩니다.
Fifty 1 Labs (OTC : FITY), une entreprise spécialisée dans les solutions de santé et bien-être alimentées par l'intelligence artificielle, a annoncé une téléconférence virtuelle pour les actionnaires prévue le 28 juillet 2025 à 12h00 EST. L'événement mettra en vedette le lauréat du prix Nobel de la paix, Dr James Orbinski, et présentera l'équipe de direction de classe mondiale de l'entreprise.
L'entreprise a présenté sa feuille de route stratégique, comprenant un investissement de 1 million de dollars en R&D pour les thérapies basées sur l'IA, des projets d'acquisition biotech de 5 à 10 millions de dollars d'ici juillet 2027, ainsi que l'intention de monter en gamme vers l'OTCQB au premier trimestre 2026. La direction a démontré son engagement en investissant personnellement 350 000 dollars et en reportant les salaires jusqu'à atteindre une valorisation de 50 millions de dollars.
L'équipe de direction comprend le PDG Paul Arora, le Dr James Orbinski en tant que scientifique principal, ainsi que d'autres experts renommés en biotechnologie, IA et santé. L'entreprise se concentre sur le repositionnement de médicaments piloté par l'IA sur le marché de la médecine fonctionnelle, dont la croissance est projetée à un TCAC de 10,9 % jusqu'en 2030.
Fifty 1 Labs (OTC: FITY), ein Unternehmen für KI-gestützte Gesundheits- und Wellnesslösungen, kündigte eine virtuelle Aktionärstelefonkonferenz für den 28. Juli 2025 um 12:00 Uhr EST an. Die Veranstaltung wird Nobelpreisträger Dr. James Orbinski präsentieren und das erstklassige Führungsteam des Unternehmens vorstellen.
Das Unternehmen stellte seine strategische Roadmap vor, einschließlich einer F&E-Investition von 1 Million US-Dollar in KI-Therapien, Plänen für eine Biotech-Akquisition im Wert von 5-10 Millionen US-Dollar bis Juli 2027 und der Absicht, im ersten Quartal 2026 auf OTCQB aufzusteigen. Das Management zeigte Engagement, indem es persönlich 350.000 US-Dollar investierte und Gehälter zurückstellte, bis eine Bewertung von 50 Millionen US-Dollar erreicht wird.
Das Führungsteam umfasst CEO Paul Arora, Dr. James Orbinski als leitenden Wissenschaftler sowie weitere namhafte Experten aus den Bereichen Biotechnologie, KI und Gesundheitswesen. Das Unternehmen konzentriert sich auf KI-gesteuerte Wirkstoff-Neuzulassungen im Functional-Medicine-Markt, der voraussichtlich mit einer jährlichen Wachstumsrate (CAGR) von 10,9 % bis 2030 wächst.
- Management team personally invested $350,000 and deferred salaries, showing strong alignment with shareholders
- Strategic $1 million R&D investment planned for AI therapies development
- Planned uplisting to OTCQB by Q1 2026 could improve stock liquidity
- Strong leadership team including Nobel Peace Prize recipient and industry experts
- Significant future capital requirements with planned $5-10 million acquisition
- Currently trading on OTC markets, which may limit institutional investment
- Management salary deferrals contingent on reaching $50 million valuation indicates current early-stage status
SEATTLE, July 28, 2025 (GLOBE NEWSWIRE) -- Fifty 1 Labs, Inc. (OTC: FITY), a leader in AI-powered health and wellness solutions, today announced it will host a virtual shareholder teleconference on Monday, July 28, 2025, at 12:00 PM EST. The event will be broadcast on X (formerly Twitter), featuring Nobel Peace Prize recipient Dr. James Orbinski, who accepted the 1999 Nobel Peace Prize on behalf of Médecins Sans Frontières (Doctors Without Borders) for the organization's groundbreaking humanitarian medical aid in crisis zones worldwide. Dr. Orbinski's involvement highlights the company's commitment to global health innovation. Viewers can access the video teleconference directly on X by following @Fifty1Labs or searching for the live stream at the scheduled time.
The teleconference will showcase Fifty 1 Labs' world-class leadership team, including Dr. Orbinski as Senior Scientist, and provide insights into the company's strategic roadmap, with a focus on advancements in its subsidiary Fifty 1 AI Labs. Key talking points from the event include:
AI-Driven Drug Repurposing and Functional Medicine Leadership: Fifty 1 AI Labs' proprietary AI platform accelerates the repurposing of off-patent compounds, reducing development costs and enabling personalized wellness solutions. This positions the company to capture significant market share in functional medicine, projected to grow at a
Strategic Roadmap Pillars: The company's plan focuses on three core areas: (1) Innovation through a
Management Commitment and Alignment: The leadership team has demonstrated strong confidence by personally investing
Expert Leadership Team: Led by CEO Paul Arora, a biotech veteran with successful exits in health tech, the team includes Nobel Peace Prize recipient James Orbinski (Senior Scientist), who accepted the 1999 Nobel Peace Prize for Médecins Sans Frontières and co-founded the Drugs for Neglected Diseases initiative (DNDi); Chief Medical Officer Nima Sakian, a pioneer in anti-aging and functional medicine; CTO Alind Gupta, an AI and health analytics expert; Scientific Advisors Edward Mills (founder of the award-winning TOGETHER Trial) and Kristian Thorlund (top
Differentiation in AI Drug Development: Unlike traditional models, Fifty 1 AI Labs emphasizes off-patent repurposing with real-world clinical data and adaptive trials for faster, safer, and more affordable therapies. The team's global health and wellness expertise enables unique market positioning, including partnerships with leading universities for evidence-based supplements.
Team Cohesion and Academic Rigor: With decades of collaboration across clinical, tech, and global health sectors, the team operates with trust and scientific rigor, leveraging academic partnerships for cutting-edge research and peer-reviewed decision-making.
During the teleconference, the leadership team will address forward-looking strategies, including potential risks, and invite shareholders to submit questions post-event to IR@fifty1labs.com for future engagement. A recording will be available on the company's website following the broadcast.
"We are excited to share our transformative vision with shareholders," said Paul Arora, CEO of Fifty 1 Labs. "By harnessing AI to redefine preventative healthcare, we are not only pursuing exponential growth but also creating lasting value for our investors, partners, and patients."
For more details on the teleconference or to access related materials, visit www.fifty1ailabs.com. Shareholders are encouraged to tune in live on X at 12:00 PM EST on July 28, 2025.
About Fifty 1 Labs, Inc.
Fifty 1 Labs, Inc. (OTC: FITY) is a forward-thinking company dedicated to AI-driven innovations in functional medicine and wellness. Through its subsidiary Fifty 1 AI Labs, the company leverages artificial intelligence to repurpose drugs and develop personalized health solutions, targeting high-growth markets in biotech and preventative care.
Investor Contact:
Investor Relations
Fifty 1 Labs, Inc.
Email: IR@fifty1labs.com
Phone: (877) 505-5006
Website: www.fifty1ailabs.com
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's future financial and operating performance, business strategy, plans, objectives, and expectations regarding future events or performance. These statements are based on current expectations, estimates, forecasts, and projections, and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The company undertakes no obligation to update or revise any forward-looking statements, except as required by law. For additional details, refer to the company's filings with the Securities and Exchange Commission.
Wire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
When is Fifty 1 Labs (FITY) hosting its virtual shareholder teleconference?
Who is Dr. James Orbinski and what is his role at Fifty 1 Labs (FITY)?
What are Fifty 1 Labs' (FITY) main strategic goals for 2025-2027?
How much has the management team invested in Fifty 1 Labs (FITY)?
What is Fifty 1 Labs' (FITY) main business focus?
